Rakesh Jain - Tekla Healthcare Insider

XHQHX -- USA Fund  

USD 23.92  0.08  0.33%

Independent Trustee

Dr. Rakesh K. Jain, Ph.D., is an Independent Trustee of HQ Healthcare Investors. Dr. Rakesh Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital, providing each Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain cofounded XTuit Pharmaceuticals, Inc. in 2011, where he also serves as a board member. He serves on the Governance and Nominating Committee of each Fund. Prior to joining Harvard, he was professor of chemical engineering at Columbia University and Carnegie Mellon University. Dr. Jain is regarded as a pioneer in the fields of tumor biology, drug delivery, in vivo imaging and bioengineering. Dr. Jain has authored more than 600 publications. He serves on advisory panels to government, industry and academia, and has served or continues to serve on editorial advisory boards of twenty journals, including Journal of Clinical Oncology and Nature Reviews Clinical Oncology. He has received more than 70 major awards and lectureships, including a Guggenheim Fellowship, the Humboldt Senior Scientist Award, the National Cancer Institute Research Career Development Award and Outstanding Investigator Grant, the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards, the Distinguished Service Award from Nature Biotechnology and the Innovator Award from the DoD Breast Cancer Program. He is a member of all three branches of US National Academies the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences and is a member of the American Academy of Arts and Sciences.
Age: 66  Executive Since 2007      

Management Performance (%)

Similar Money Managers

Showing few of many executives

One Year Return

Joshua BarrickmanVanguard Total Bond Market Inde
8.18%
Joseph LoughreyVanguard Total Bond Market Inde
8.57%
Rajiv GuptaVanguard Total Bond Market Inde
8.18%
Emerson FullwoodVanguard Total Bond Market Inde
8.57%
Peter VolanakisVanguard Total Bond Market Inde
8.18%
Amy GutmannVanguard Total Bond Market Inde
8.57%
Alan WilsonAmerican Funds Growth Fund of A
0.0%
JoAnn HeisenVanguard Total Bond Market Inde
8.18%
Rajiv GuptaVanguard Total Bond Market Inde
8.57%
Heidi StamVanguard Total Bond Market Inde
8.57%
Andre PeroldVanguard Total Bond Market Inde
8.18%
Dina PerryAmerican Funds Income Fund of A
6.36%
Emerson FullwoodVanguard Total Bond Market Inde
8.18%
John SmetAmerican Funds American Balance
5.87%
Dina PerryAmerican Funds Income Fund of A
5.52%
JoAnn HeisenVanguard Total Bond Market Inde
8.57%
Michael PerreVanguard Developed Markets Inde
18.72%
Peter VolanakisVanguard Total Bond Market Inde
8.57%
Alfred MurataPimco Income Fund Class I-3
0.0%
Kathryn HyattVanguard Total Bond Market Inde
8.57%
Kathryn HyattVanguard Total Bond Market Inde
8.18%

Fund Summary

The fund is listed under null category and is part of null family.

Tekla Healthcare Inv Leadership Team

William Reardon, Executive, CPA
Michael Bonney, Executive
Oleg Pohotsky, Chairman, MBA
Laura Woodward, Executive, CPA
Lucinda Stebbins, Executive, CPA
Daniel Omstead, President
Uwe Reinhardt, Executive, Ph.D
Rakesh Jain, Executive

Fund Performance Indicators

Current Sentiment - XHQHX

Tekla Healthcare Inv Investor Sentiment
Macroaxis portfolio users are unemotional in their outlook on investing in Tekla Healthcare Investors. What is your outlook on investing in Tekla Healthcare Investors? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Also Currentnly Active
Purchased over 100 shares of
over a week ago
Traded for 10.44
Purchased over 300 shares of
over a week ago
Traded for 6.24
Purchased over 70 shares of
over a week ago
Traded for 23.42
See also Your Current Watchlist. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.